Relmada Therapeutics Stock (NASDAQ:RLMD)
Previous Close
$0.31
52W Range
$0.24 - $4.72
50D Avg
$0.29
200D Avg
$1.93
Market Cap
$9.69M
Avg Vol (3M)
$920.56K
Beta
0.41
Div Yield
-
RLMD Company Profile
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CSBR | Champions Oncology, Inc. |
| NUVB | Nuvation Bio Inc. |
| RVMD | Revolution Medicines, Inc. |
| IPSC | Century Therapeutics, Inc. |
| BCYC | Bicycle Therapeutics plc |
| PMVP | PMV Pharmaceuticals, Inc. |
| RAPT | RAPT Therapeutics, Inc. |
| NAMS | NewAmsterdam Pharma Company N.V. |
| DYN | Dyne Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| CYTK | Cytokinetics, Incorporated |
| THRD | Third Harmonic Bio, Inc. |
| STTK | Shattuck Labs, Inc. |